dinoprost and Uterine-Cervicitis

dinoprost has been researched along with Uterine-Cervicitis* in 2 studies

Trials

1 trial(s) available for dinoprost and Uterine-Cervicitis

ArticleYear
Bovine lactoferrin in preventing preterm delivery associated with sterile inflammation.
    Biochemistry and cell biology = Biochimie et biologie cellulaire, 2012, Volume: 90, Issue:3

    Preterm delivery (PTD) occurs before the 37th week of gestation. Iron deficiency anemia and inflammatory processes either related to infection or sterile inflammatory response represent risk factors for PTD. Bovine lactoferrin (bLf), an emerging important regulator of iron and inflammatory homeostasis, can represent a new therapeutic approach for PTD treatment. Here an open-label cohort and subcohort study is reported. The cohort was designed to assess the effect of bLf oral administration on iron and inflammatory homeostasis in anemic pregnant women. The subcohort including women of the cohort with PTD threat was additionally treated with bLf intravaginal administration. A significant improvement of hematological parameters was observed in the women's cohort together with a consistent decrease of serum interleukin-6 (IL-6) levels. Combined administration of oral and intravaginal bLf to the women's subcohort with PTD threat decreased IL-6 in both serum and cervicovaginal fluids, cervicovaginal prostaglandin F(2α), and suppressed uterine contractility. BLf administration blocked further shortening of cervical length and the increase of fetal fibronectin thus prolonging the length of pregnancy. The deliveries occurred between the 37th and 38th week of gestation. These results provide strong evidence for a role of bLf in PTD treatment, thus extending the therapeutic potential of this multifunctional natural protein.

    Topics: Administration, Intravaginal; Administration, Oral; Anemia, Iron-Deficiency; Animals; Cattle; Cervix Uteri; Dinoprost; Female; Humans; Immunologic Factors; Interleukin-6; Lactoferrin; Pregnancy; Pregnancy Complications; Premature Birth; Risk Factors; Treatment Outcome; Uterine Cervicitis

2012

Other Studies

1 other study(ies) available for dinoprost and Uterine-Cervicitis

ArticleYear
Characteristics of repeat breeding buffaloes in Nepal.
    The Journal of reproduction and development, 2006, Volume: 52, Issue:3

    Repeat breeding is one of the most important reproductive disorders in buffaloes. Its etiology, however, is not well described. The aim of this study was to show the clinical features of repeat breeding buffaloes referred to infertility camps in the southern region of Nepal. Eighty-five buffaloes mated three times or more without conception were clinically examined. Sixty percent of the buffaloes were heifers. Fifty-nine percent of the buffalo cows with repeat breeding were already 10 months or more after calving. Indications of cervicitis were observed in 25% of the repeat breeders. Buffalo cows 12 months or more after calving and heifers in adequate nutritional condition were treated with either GnRH or PGF2alpha, and showed a satisfactory conception rate after treatment. Cows within 12 months post partum and heifers at a relatively younger age were treated with a vitamin/mineral mixture supplement, and this resulted in a moderate conception rate. In conclusion, the major clinical features of repeat breeding buffaloes include a large proportion of heifers, a long interval from calving to treatment, a high incidence of cervicitis, and a high or moderate response to treatment with PGF2alpha and GnRH or vitamin/mineral mixture. More attention needs to be paid to estrous detection and management of mating with bulls.

    Topics: Age Factors; Animals; Breeding; Buffaloes; Dinoprost; Female; Gonadotropin-Releasing Hormone; Infertility, Female; Nepal; Treatment Outcome; Uterine Cervicitis; Vitamins

2006